{
  "aspirin+warfarin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Both drugs affect blood clotting - aspirin inhibits platelet aggregation, warfarin inhibits vitamin K-dependent clotting factors",
    "clinical_effect": "Significantly increased risk of bleeding, including gastrointestinal and intracranial hemorrhage",
    "recommendation": "Avoid combination if possible. If necessary, use lowest effective doses and monitor INR closely.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "aspirin+ibuprofen": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Both are NSAIDs that inhibit COX enzymes, leading to additive effects on gastric mucosa and platelet function",
    "clinical_effect": "Increased risk of gastrointestinal bleeding and ulceration. Ibuprofen may reduce cardioprotective effects of aspirin.",
    "recommendation": "Avoid concurrent use if possible. If needed, take ibuprofen at least 2 hours after aspirin. Monitor for GI symptoms.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "ibuprofen+warfarin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Ibuprofen (NSAID) inhibits platelet function and may displace warfarin from protein binding sites, increasing free warfarin levels",
    "clinical_effect": "Markedly increased risk of bleeding, particularly gastrointestinal bleeding",
    "recommendation": "Avoid combination. Consider alternative pain relief (e.g., acetaminophen). If unavoidable, monitor INR closely and watch for bleeding.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "ibuprofen+lisinopril": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "NSAIDs can reduce the antihypertensive effect of ACE inhibitors and increase risk of renal impairment",
    "clinical_effect": "Decreased blood pressure control, potential acute kidney injury, hyperkalemia",
    "recommendation": "Monitor blood pressure and renal function. Use lowest effective NSAID dose for shortest duration. Consider alternative pain relief.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },

  "atorvastatin+metformin": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "No significant pharmacokinetic or pharmacodynamic interaction",
    "clinical_effect": "Generally safe combination. May have additive benefits for cardiovascular risk reduction in diabetic patients.",
    "recommendation": "No special precautions needed. Routine monitoring of glucose and lipids as indicated.",
    "source": "Clinical studies",
    "evidence_level": "well-documented"
  },
  "lisinopril+metformin": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "No significant interaction. Both commonly used together in diabetic patients with hypertension.",
    "clinical_effect": "Generally safe and often beneficial combination for diabetic patients",
    "recommendation": "Monitor renal function periodically as both drugs are renally excreted. Standard diabetes and hypertension monitoring.",
    "source": "Clinical practice guidelines",
    "evidence_level": "well-documented"
  },
  "amlodipine+atorvastatin": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "Amlodipine may slightly increase atorvastatin levels via CYP3A4 inhibition",
    "clinical_effect": "Minimal clinical significance. Slight increase in statin exposure may increase efficacy but also risk of myopathy.",
    "recommendation": "Generally safe combination. Monitor for muscle pain or weakness. Consider starting with lower atorvastatin dose.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "clopidogrel+omeprazole": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Omeprazole inhibits CYP2C19, reducing conversion of clopidogrel to its active metabolite",
    "clinical_effect": "Reduced antiplatelet effect of clopidogrel, potentially increasing cardiovascular events",
    "recommendation": "Avoid combination if possible. Consider alternative PPI (e.g., pantoprazole) or H2 blocker. If unavoidable, separate dosing times.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "clopidogrel+pantoprazole": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "Pantoprazole has less CYP2C19 inhibition compared to omeprazole",
    "clinical_effect": "Minimal effect on clopidogrel activation. Considered safer PPI option with clopidogrel.",
    "recommendation": "Preferred PPI for patients on clopidogrel. Standard monitoring for both medications.",
    "source": "Clinical studies",
    "evidence_level": "well-documented"
  },
  "levothyroxine+omeprazole": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "PPIs may reduce gastric acidity, potentially affecting levothyroxine absorption",
    "clinical_effect": "Possible decreased levothyroxine absorption, may require dose adjustment",
    "recommendation": "Monitor TSH levels. Take levothyroxine on empty stomach, at least 30-60 minutes before omeprazole.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "moderate"
  },
  "gabapentin+tramadol": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Additive CNS depressant effects",
    "clinical_effect": "Increased sedation, dizziness, respiratory depression risk",
    "recommendation": "Use with caution. Start with lower doses. Avoid driving or operating machinery. Monitor for excessive sedation.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "lisinopril+losartan": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Both act on renin-angiotensin system (ARB + ACE inhibitor)",
    "clinical_effect": "Increased risk of hypotension, hyperkalemia, and renal impairment without additional benefit",
    "recommendation": "Generally not recommended. Use one or the other, not both. If combined, monitor BP, potassium, and renal function closely.",
    "source": "Clinical practice guidelines",
    "evidence_level": "well-documented"
  },
  "atorvastatin+simvastatin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Both are statins - no reason to combine, only increases risk",
    "clinical_effect": "Significantly increased risk of myopathy, rhabdomyolysis, liver toxicity",
    "recommendation": "Never combine statins. Use one statin at appropriate dose. This is likely a prescribing error.",
    "source": "Clinical pharmacology",
    "evidence_level": "well-documented"
  },
  "aspirin+metformin": {
    "risk_level": "none",
    "severity": "none",
    "mechanism": "No significant interaction",
    "clinical_effect": "Safe combination, commonly used together in diabetic patients for cardiovascular protection",
    "recommendation": "No special precautions. Standard monitoring for each medication.",
    "source": "Clinical practice",
    "evidence_level": "well-documented"
  },
  "metformin+warfarin": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "No direct interaction, but both require monitoring",
    "clinical_effect": "Generally safe combination. Metformin may rarely affect warfarin metabolism.",
    "recommendation": "Monitor INR as usual for warfarin. Standard diabetes monitoring for metformin.",
    "source": "Clinical practice",
    "evidence_level": "moderate"
  },
  "amlodipine+lisinopril": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "Complementary mechanisms - calcium channel blocker + ACE inhibitor",
    "clinical_effect": "Additive blood pressure lowering effect. Often used together for better BP control.",
    "recommendation": "Monitor blood pressure. Watch for excessive hypotension, especially when initiating or increasing doses.",
    "source": "Clinical practice guidelines",
    "evidence_level": "well-documented"
  },
  "atorvastatin+levothyroxine": {
    "risk_level": "none",
    "severity": "none",
    "mechanism": "No significant interaction",
    "clinical_effect": "Safe combination, commonly prescribed together",
    "recommendation": "No special precautions. Monitor TSH and lipids as clinically indicated.",
    "source": "Clinical practice",
    "evidence_level": "well-documented"
  },
  "gabapentin+metformin": {
    "risk_level": "none",
    "severity": "none",
    "mechanism": "No significant interaction",
    "clinical_effect": "Safe combination, often used together in diabetic neuropathy",
    "recommendation": "No special precautions. Standard monitoring for each medication.",
    "source": "Clinical practice",
    "evidence_level": "well-documented"
  },
  "omeprazole+tramadol": {
    "risk_level": "low",
    "severity": "minor",
    "mechanism": "Minimal interaction. Omeprazole may slightly affect tramadol metabolism.",
    "clinical_effect": "Generally safe combination. Possible minor changes in tramadol effectiveness.",
    "recommendation": "No special precautions. Monitor pain control and side effects as usual.",
    "source": "Clinical pharmacology",
    "evidence_level": "moderate"
  },
  "fluoxetine+tramadol": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Both drugs increase serotonin levels; Fluoxetine inhibits CYP2D6 which metabolizes tramadol",
    "clinical_effect": "Risk of Serotonin Syndrome (agitation, hallucinations, rapid rate, fever). Reduced pain relief from tramadol.",
    "recommendation": "Avoid combination. Use alternative analgesic. If necessary, monitor closely for signs of serotonin toxicity.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "sertraline+tramadol": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Additive serotonergic effects",
    "clinical_effect": "Increased risk of Serotonin Syndrome. May lower seizure threshold.",
    "recommendation": "Use with caution. Monitor for signs of serotonin syndrome. Consider lower doses.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "fluoxetine+warfarin": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Fluoxetine may inhibit warfarin metabolism via CYP2C9 and has antiplatelet effects",
    "clinical_effect": "Increased bleeding risk and potential INR elevation",
    "recommendation": "Monitor INR closely when starting or stopping fluoxetine. Monitor for bleeding.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "ciprofloxacin+warfarin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Ciprofloxacin inhibits CYP1A2 and CYP3A4, reducing warfarin metabolism",
    "clinical_effect": "Significantly increased INR and bleeding risk",
    "recommendation": "Avoid if possible or reduce warfarin dose preemptively. Monitor INR closely.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "lisinopril+spironolactone": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Both drugs reduce potassium excretion (ACE inhibitor + K-sparing diuretic)",
    "clinical_effect": "Significant risk of hyperkalemia (high potassium), potentially leading to cardiac arrhythmias",
    "recommendation": "Monitor serum potassium and renal function closely. Avoid high-potassium diet.",
    "source": "Clinical practice guidelines",
    "evidence_level": "well-documented"
  },
  "amiodarone+digoxin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Amiodarone increases digoxin levels via P-gp inhibition",
    "clinical_effect": "Increased risk of digoxin toxicity (nausea, arrhythmias, visual changes)",
    "recommendation": "Reduce digoxin dose by 30-50% if amiodarone is added. Monitor digoxin levels.",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "amiodarone+simvastatin": {
    "risk_level": "high",
    "severity": "major",
    "mechanism": "Amiodarone inhibits CYP3A4, increasing simvastatin levels",
    "clinical_effect": "Increased risk of myopathy and rhabdomyolysis",
    "recommendation": "Limit simvastatin dose to 20mg/day or switch to a non-CYP3A4 statin (e.g., rosuvastatin).",
    "source": "FDA Drug Interactions Database",
    "evidence_level": "well-documented"
  },
  "alprazolam+oxycodone": {
    "risk_level": "high",
    "severity": "critical",
    "mechanism": "Additive CNS depression (Benzo + Opioid)",
    "clinical_effect": "Profound sedation, respiratory depression, coma, death. FDA Black Box Warning.",
    "recommendation": "Avoid combination. If necessary, limit dosages and duration. Monitor closely for respiratory depression.",
    "source": "FDA Black Box Warning",
    "evidence_level": "well-documented"
  },
  "diazepam+hydrocodone": {
    "risk_level": "high",
    "severity": "critical",
    "mechanism": "Additive CNS depression (Benzo + Opioid)",
    "clinical_effect": "Profound sedation, respiratory depression, coma, death. FDA Black Box Warning.",
    "recommendation": "Avoid combination. If necessary, limit dosages and duration. Monitor closely for respiratory depression.",
    "source": "FDA Black Box Warning",
    "evidence_level": "well-documented"
  },
  "amoxicillin+azithromycin": {
    "risk_level": "none",
    "severity": "none",
    "mechanism": "Different mechanisms of action",
    "clinical_effect": "Generally safe, though combining antibiotics increases risk of diarrhea/C. diff.",
    "recommendation": "No specific interaction. Ensure indication for dual therapy exists (e.g., H. pylori, pneumonia).",
    "source": "Clinical practice",
    "evidence_level": "well-documented"
  },
  "amoxicillin+clavulanate": {
    "risk_level": "none",
    "severity": "none",
    "mechanism": "Synergistic effect (this is Augmentin)",
    "clinical_effect": "Therapeutic combination.",
    "recommendation": "Standard dosing.",
    "source": "Standard Therapy",
    "evidence_level": "well-documented"
  },
  "calcium+doxycycline": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Calcium binds to tetracyclines in the gut, reducing absorption",
    "clinical_effect": "Reduced efficacy of the antibiotic",
    "recommendation": "Separate doses by at least 2 hours.",
    "source": "FDA Labeling",
    "evidence_level": "well-documented"
  },
  "antacids+ciprofloxacin": {
    "risk_level": "moderate",
    "severity": "moderate",
    "mechanism": "Cations (Mg, Al, Ca) bind to ciprofloxacin reducing absorption",
    "clinical_effect": "Reduced efficacy of ciprofloxacin",
    "recommendation": "Take ciprofloxacin 2 hours before or 6 hours after antacids.",
    "source": "FDA Labeling",
    "evidence_level": "well-documented"
  },
  "alcohol+clonazepam": {
    "risk_level": "high",
    "severity": "critical",
    "mechanism": "Additive CNS depression",
    "clinical_effect": "Severe sedation, respiratory depression, impairment.",
    "recommendation": "Strictly avoid alcohol while taking this medication.",
    "source": "FDA Labeling",
    "evidence_level": "well-documented"
  },
  "alcohol+metrogyl": {
    "risk_level": "high",
    "severity": "moderate",
    "mechanism": "Disulfiram-like reaction inhibition of aldehyde dehydrogenase",
    "clinical_effect": "Flushing, vomiting, tachycardia (Antabuse reaction).",
    "recommendation": "Avoid alcohol during and for 48 hours after treatment.",
    "source": "FDA Labeling",
    "evidence_level": "well-documented"
  },
  "nitrates+sildenafil": {
    "risk_level": "high",
    "severity": "critical",
    "mechanism": "Synergistic vasodilation (PDE5 inhibitor + Nitric Oxide donor)",
    "clinical_effect": "Severe, life-threatening hypotension",
    "recommendation": "CONTRAINDICATED. Never use together.",
    "source": "FDA Contraindication",
    "evidence_level": "critical"
  },
  "alcohol+tylenol": {
    "risk_level": "moderate",
    "severity": "major",
    "mechanism": "Increased production of toxic metabolite NAPQI via CYP2E1 induction",
    "clinical_effect": "Increased risk of liver toxicity/failure",
    "recommendation": "Avoid excessive alcohol. Do not exceed 4g acetaminophen daily.",
    "source": "FDA Labeling",
    "evidence_level": "well-documented"
  }
}
